MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has successfully implanted its AIGISRx® Antibacterial Technology in 20,000 patients in the United States.
